Targeting DNA damage response in HPV-related head and neck cancer
Targeting the DNA Damage Response in HPV+ Head and Neck Cancer
This study is looking at how the HPV virus affects DNA in head and neck cancer and is testing a new treatment that could help patients avoid harsh side effects from standard therapies, aiming to make their treatment easier and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11117189 on NIH RePORTER |
What this research studies
This research focuses on understanding how the human papillomavirus (HPV) affects DNA damage response mechanisms in head and neck squamous cell carcinoma (HNSCC). The study aims to explore the role of HPV's E6 and E7 proteins in disrupting tumor suppressor pathways and causing genomic instability. By investigating the effects of a specific inhibitor called AZD1775 on HPV+ HNSCC tumors, the research seeks to develop targeted therapies that could reduce the need for traditional chemoradiotherapy, which often leads to long-term side effects for patients. The ultimate goal is to improve treatment outcomes and quality of life for patients with this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HPV-positive head and neck squamous cell carcinoma.
Not a fit: Patients with HPV-negative head and neck cancers or those with other unrelated malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with HPV-positive head and neck cancer.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting DNA damage response in cancer treatment, indicating potential for success in this area.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Diab, Ahmed Mohamed — University of Pennsylvania
- Study coordinator: Diab, Ahmed Mohamed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.